Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 4532990

Next Previous
Drug Profile

GSK 4532990

Alternative Names: ARO-HSD; GSK-4532990; VSA-006

Latest Information Update: 24 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Arrowhead Pharmaceuticals; GSK
  • Class Amino sugars; Drug conjugates; Hepatoprotectants; Small interfering RNA
  • Mechanism of Action 17 hydroxysteroid dehydrogenase expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic liver disorders; Non-alcoholic steatohepatitis

Most Recent Events

  • 24 Feb 2025 Phase-II clinical trials in Alcoholic liver disorders (Parenteral), before February 2025 (GSK pipeline, February 2025)
  • 27 Sep 2024 GlaxoSmithKline plans a phase II STARLIGHT trial for Alcoholic liver disorders in Australia, Canada, Denmark, France, Germany, Italy, Japan, Mexico, South Korea, Spain, Sweden, Turkey, United Kingdom, and USA (NCT06613698)
  • 21 Mar 2024 Visirna Therapeutics plans a phase II trial for Non-alcoholic steatohepatitis (SC, Injection) (NCT06322628 )

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top